成人黄色免费看国产精品在线_产日韩欧美一区二区东京热_性色国产福利在线_久久伊人五月天论坛_免费电影AV网站_娴熟骚妇在家看中文字幕_九九热线精品视频16_亚洲欧美日韩激情蜜桃_97人妻免费专区_野外农村经典三级在线观看

掃碼關(guān)注公眾號           掃碼咨詢技術(shù)支持           掃碼咨詢技術(shù)服務(wù)
  
客服熱線:400-901-9800  客服QQ:4009019800  技術(shù)答疑  技術(shù)支持  質(zhì)量反饋  關(guān)于我們  聯(lián)系我們
千年殇,择天记
首頁 > 產(chǎn)品中心 > 一抗 > 產(chǎn)品信息
Anti-DLL4 & VEGF Reference Antibody (Navicixizumab Biosimilar) (BIO0998SM)  
訂購熱線:400-901-9800
訂購郵箱:sales@bioss.com.cn
訂購QQ:  400-901-9800
技術(shù)支持:techsupport@bioss.com.cn
100ug/詢價
1mg/詢價
5mg/詢價
大包裝/詢價

產(chǎn)品編號 BIO0998SM
英文名稱 Anti-DLL4 & VEGF Reference Antibody (Navicixizumab Biosimilar)
別    名 DLL4 & VEGF; Navicixizumab  
抗體來源
克隆類型 Monoclonal
交叉反應(yīng) Human
產(chǎn)品應(yīng)用
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理論分子量 146.17kDa
性    狀 Lyophilized
亞    型 IgG-like
純化方法 Protein A
緩 沖 液 100 mM Pro-Ac 20mM Arg pH 5.0
保存條件 -80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions;Avoid repeated freeze-thaw cycles.
注意事項 This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed PubMed
產(chǎn)品介紹
產(chǎn)品圖片
To evaluate the neutralizing activity of Navicixizumab against VEGF. Co-incubation of Navicixizumab with VEGF protein, then with the addition of VEGF-NF-AT-HEK293 cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Navicixizumab can neutralize VEGF-165, and the IC50 was 7.957 nM.
Navicixizumab bound to huDLL4-FL-HEK293 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Navicixizumab bound to huDLL4-FL-HEK293 cells, and the EC50 was 4.603 nM.
Navicixizumab bound to VEGFA protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Navicixizumab bound to huVEGFA-His, and the EC50 was 0.020 nM.
Navicixizumab bound to DLL4 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Navicixizumab bound to huDLL4-His, and the EC50 was 0.033 nM.
The purity of Anti-DLL4 & VEGF Reference Antibody (Navicixizumab) is 97.99%, determined by SEC-HPLC.
Anti-DLL4 & VEGF Reference Antibody (Navicixizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
版權(quán)所有 2004-2026 72ec.cn 北京博奧森生物技術(shù)有限公司
通過國際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號: 00124Q34771R2M/1100
通過國際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號: CQC24QY10047R0M/1100
京ICP備05066980號-1         京公網(wǎng)安備110107000727號